Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
01 02 2023
Historique:
received: 26 11 2021
pubmed: 7 4 2022
medline: 3 2 2023
entrez: 6 4 2022
Statut: ppublish

Résumé

Data from the first wave of the coronavirus disease 2019 (COVID-19) pandemic suggested that patients with inflammatory bowel disease (IBD) are not at higher risk of being infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population and that a worse prognosis is not associated with immunomodulatory drugs, with the possible exception of systemic steroids. This retrospective, observational study included consecutive IBD patients from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) cohort who had a SARS-CoV-2 infection diagnosis (polymerase chain reaction-confirmed presence of the viral genome in a nasopharyngeal swab) during the second COVID-19 pandemic wave (September 2020 to December 2020). Data regarding demographics, IBD features and treatments, and comorbidities were analyzed in correlation with COVID-19 clinical outcomes. Data on 122 patients (mean age, 43.9 ± 16.7 years; males, 50.0%; Crohn's disease, 62.3%; ulcerative colitis, 37.7%) were reported. Twelve patients developed COVID-19-related pneumonia (9.8%), 4 (3.3%) required respiratory assistance (nonmechanical ventilation or orotracheal intubation), and 4 died (case fatality rate, 3.3%). In a multivariable analysis, age (odds ratio [OR], 1.034; 95% CI, 1.006-1.147; P = .032) and severe IBD activity (OR, 13.465; 95% CI, 1.104-164.182; P = .042) were independent predictors of COVID-19-related pneumonia, while severe IBD activity (OR, 15.359; 95% CI, 1.320-178.677; P = .030) was the only independent predictor of severe COVID-19, a composite endpoint defined as the need for respiratory assistance or death. A trend towards a protective role of tumor necrosis factor α inhibitors on pneumonia development was reported (P = .076). In this cohort of patients with IBD and SARS-CoV-2 infection, severe IBD activity was the only independent risk factor for severe COVID-19. This retrospective, observational study on patients with inflammatory bowel disease and severe acute respiratory syndrome coronavirus 2 infection showed that severe inflammatory bowel disease activity was the only independent risk factor for severe coronavirus disease 2019.

Sections du résumé

BACKGROUND
Data from the first wave of the coronavirus disease 2019 (COVID-19) pandemic suggested that patients with inflammatory bowel disease (IBD) are not at higher risk of being infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population and that a worse prognosis is not associated with immunomodulatory drugs, with the possible exception of systemic steroids.
METHODS
This retrospective, observational study included consecutive IBD patients from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) cohort who had a SARS-CoV-2 infection diagnosis (polymerase chain reaction-confirmed presence of the viral genome in a nasopharyngeal swab) during the second COVID-19 pandemic wave (September 2020 to December 2020). Data regarding demographics, IBD features and treatments, and comorbidities were analyzed in correlation with COVID-19 clinical outcomes.
RESULTS
Data on 122 patients (mean age, 43.9 ± 16.7 years; males, 50.0%; Crohn's disease, 62.3%; ulcerative colitis, 37.7%) were reported. Twelve patients developed COVID-19-related pneumonia (9.8%), 4 (3.3%) required respiratory assistance (nonmechanical ventilation or orotracheal intubation), and 4 died (case fatality rate, 3.3%). In a multivariable analysis, age (odds ratio [OR], 1.034; 95% CI, 1.006-1.147; P = .032) and severe IBD activity (OR, 13.465; 95% CI, 1.104-164.182; P = .042) were independent predictors of COVID-19-related pneumonia, while severe IBD activity (OR, 15.359; 95% CI, 1.320-178.677; P = .030) was the only independent predictor of severe COVID-19, a composite endpoint defined as the need for respiratory assistance or death. A trend towards a protective role of tumor necrosis factor α inhibitors on pneumonia development was reported (P = .076).
CONCLUSIONS
In this cohort of patients with IBD and SARS-CoV-2 infection, severe IBD activity was the only independent risk factor for severe COVID-19.
This retrospective, observational study on patients with inflammatory bowel disease and severe acute respiratory syndrome coronavirus 2 infection showed that severe inflammatory bowel disease activity was the only independent risk factor for severe coronavirus disease 2019.

Autres résumés

Type: plain-language-summary (eng)
This retrospective, observational study on patients with inflammatory bowel disease and severe acute respiratory syndrome coronavirus 2 infection showed that severe inflammatory bowel disease activity was the only independent risk factor for severe coronavirus disease 2019.

Identifiants

pubmed: 35385102
pii: 6564282
doi: 10.1093/ibd/izac064
pmc: PMC9383704
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-221

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Fabio Salvatore Macaluso (FS)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Alessandra Giuliano (A)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Walter Fries (W)

Inflammatory Bowel Disease Unit, Policlinico "G. Martino," Messina, Italy.

Anna Viola (A)

Inflammatory Bowel Disease Unit, Policlinico "G. Martino," Messina, Italy.

Alfredo Abbruzzese (A)

Inflammatory Bowel Disease Unit, Policlinico "G. Martino," Messina, Italy.

Maria Cappello (M)

Gastroenterology and Hepatology Section, Promise, University of Palermo, Palermo, Italy.

Enrica Giuffrida (E)

Gastroenterology and Hepatology Section, Promise, University of Palermo, Palermo, Italy.

Lucio Carrozza (L)

Gastroenterology and Hepatology Section, Promise, University of Palermo, Palermo, Italy.

Antonino Carlo Privitera (AC)

Inflammatory Bowel Disease Unit, "Cannizzaro" Hospital, Catania, Italy.

Antonio Magnano (A)

Gastroenterology Unit, Policlinico "Vittorio Emanuele," Catania, Italy.

Concetta Ferracane (C)

Gastroenterology Unit, Policlinico "Vittorio Emanuele," Catania, Italy.

Giuseppe Scalisi (G)

Gastroenterology Unit, A.R.N.A.S. "Garibaldi," Catania, Italy.

Maria Giovanna Minissale (MG)

Gastroenterology and Endoscopy Unit, "Buccheri La Ferla Fatebenefratelli" Hospital, Palermo, Italy.

Emiliano Giangreco (E)

Gastroenterology Unit, "Guzzardi" Hospital, Vittoria, Italy.

Serena Garufi (S)

Gastroenterology Unit, "S. Elia- M. Raimondi" Hospital, Caltanissetta, Italy.

Carmelo Bertolami (C)

Gastroenterology Unit, "Papardo Piemonte" Hospital, Messina, Italy.

Ugo Cucinotta (U)

Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Messina, Italy.

Francesco Graziano (F)

Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Messina, Italy.
Pediatric Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Angelo Casà (A)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Sara Renna (S)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Giulia Teresi (G)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Giulia Rizzuto (G)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Mariella Mannino (M)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Marcello Maida (M)

Gastroenterology Unit, "Papardo Piemonte" Hospital, Messina, Italy.

Ambrogio Orlando (A)

Inflammatory Bowel Disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH